Mefloquine in the treatment of cutaneous leishmaniasis

Correia, Dalmo; Silva, C. A. De Campos; Matthes, Ângelo Gustavo Zucca

doi:10.1590/s0037-86821999000500018

Cited by 4 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mefloquine, another aminoquinoline, has activity against promastigotes with an IC 50 of 8.4 µM. However, the use of mefloquine in mice and in the clinic studies does not provide good results, such as non-reduction of the lesions and no effects compared to that of the placebo groups(60)(61)(62)(63).…”

mentioning

confidence: 99%

Leishmaniasis treatment update of possibilities for drug repurposing

Torres-Santos¹

2018

Front Biosci

View full text Add to dashboard Cite

The leishmaniases represent a public health problem in under-developed countries and are considered a neglected disease by the World Health Organization (WHO). They are cuased by parasites with different clinical manifestations. Currently, there is no vaccine, and treatment is in-efficient and is associated with both serious side effects often leading to resistance to the parasites. Thus, it is essential to search for new treatment strategies, such as drug repurposing, i.e., the use of drugs that are already used for other diseases. The discovery of new clinical applications for approved drugs is strategic for lowering the cost of drug discovery since human toxicity assays are already conducted. Here, we review a broad analysis of the different aspects of this approach for anti-leishmanial treatment.

show abstract

mentioning

confidence: 99%